Xenon has entered into a strategic alliance with Merck to discover and develop small molecule candidates for the potential treatment of cardiovascular disease. Xenon will perform validation studies using its clinical genetics platform, as well as drug discovery and select preclinical development of small molecule compounds for targets selected by a joint steering committee. Merck has the option to exclusively license targets and compounds from Xenon for development and commercialization. Xeno...